马约林的在患有异位平原的病人:一个系统的审查
Miranda K Branyiczky1, Megan S Lowe2, Mohannad Abu-Hilal1,3
1Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Journal of cutaneous medicine and surgery
|October 31, 2025
概括
异位平 (ALP) 可以发展为马乔林 (MU),一种侵袭性癌症. 这份对176例病例的综述发现,ALP患者中有0.9-4.2%的患者患有MU,这凸显了早期检测和多学科护理的需要.
科学领域:
- 皮肤病学 皮肤病学
- 在瘤学瘤学.
- 病理学 病理学 病理学
背景情况:
- 无源性平坦 (ALP) 是一种慢性炎症状况.
- ALP携带患皮肤状细胞癌 (cSCC) 的风险,特别是马乔林 (MU).
研究的目的:
- 系统地审查ALP中出现的MU患者的临床特征.
- 分析ALP患者的MU治疗结果.
主要方法:
- 对MEDLINE和Embase数据库进行系统审查 (启动至2024年11月).
- 包括32项报告ALP中MU或状形的研究 (n=176例).
- 临床特征和治疗结果的描述性分析.
主要成果:
- 患者年龄较大 (平均63.9岁),主要是女性 (77.3%).
- 女性 (72.2%),男性 (22.2%) 的阴茎受伤最常见.
- 在ALP队列中,MU/cSCC的患病率为0.9-4.2%;HPV很少被检测到 (8.4%).
- 发育不良之前的平均ALP持续时间为47.5个月;45.7%的患者有转移.
- 手术切除是主要治疗方法;复发率为32.9%,死亡率为21.1%.
结论:
- ALP具有恶性潜力,需要早期检测和多学科护理.
- 疾病控制不良,侵蚀性形态和长期的病变增加了恶性瘤的风险.
- 常规的生殖器官检查,及时的活检和积极的ALP管理至关重要.
相关概念视频
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
528
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
528
Peptic Ulcer Disease II: Pathophysiology
1.9K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.9K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.4K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.4K
Peptic Ulcer Disease IV: Management
424
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
424
Peptic Ulcer Disease I: Introduction
725
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
725


